With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing opportunities, and continuing to build its product pipeline jointly with R&D.Read More
IntelGenx (OTCQX:IGXT; TSX-V:IGX) has multiple milestones on tap this year with its oral film drug delivery platform, VersaFilm, as it continues building strategic partnerships in the pharmaceutical industry.Read More
Closely-held Braeburn Pharmaceuticals, which in late May received FDA approval to market the first ever six-month implant of buprenorphine for opioid dependence, is developing a portfolio of long-acting implants and injectables that improve public health and social cost outcomes associated with drug diversion, misuse and non-compliance.
“This is the way of the future,” Behshad Sheldon, president and CEO, says in an interview with BioTuesdays.com. “In 10 years, there will be dozens and dozens of drug products available as long-acting injectables and implantables.”Read More
Concert Pharmaceuticals (NASDAQ:CNCE), which is modifying known drugs with its deuterium technology, last week initiated a multiple ascending dose Phase 1 trial with healthy volunteers of its next generation drug for cystic fibrosis (CF), CTP-656, as a stepping stone to a small Phase 2 efficacy trial in the second half of 2016.
“We hope to showcase how deuterium, a heavier form of hydrogen, can create new medicines from existing drugs to potentially enhance safety and efficacy as well as treat new indications,” Roger Tung, president and CEO, says in an interview with BioTuesdays.com.
The current trial will include three different doses of CTP-656 as well as a single dose crossover comparison of CTP-656 with Kalydeco, or ivacaftor, which is the first drug that treats the underlying cause rather than the symptoms of CF in patients with certain mutations of the disease.Read More